The Israeli company’s vision is to deliver innovative medicines to patients while fostering synergistic long-term collaborations with leading biopharmaceutical companies.

Biond’s pipeline is based on internal research of newly discovered immune-checkpoints and immuneevasion mechanisms. Its leading development programs include BND-22, a first-in-class multi-cell checkpoint inhibitor targeting ILT2, and BION-206, a novel agent developed for overcoming PD-1 blockade resistance by targeting soluble CD28; an immune evasion mechanism discovered by Biond scientists.